Dr Reddy's Laboratories Ltd on Friday announced the launch of Somazina, the innovator brand of Citicoline in the Indian market.
The Hyderabad-based company has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make the drug available in India. It is used for the treatment of post-stroke patients around the world.
It is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
Commenting on the launch, Alok Sonig, Senior Vice President and Head of India Business said: “We are excited about the partnership with Ferrer and launch of Somazina which addresses significant unmet need in patients, whose quality of life gets severely compromised after having a stroke.’’
``With the launch of Somazina and our recent acquisition of Nootropil, through the UCB brands’ acquisition, we look forward to building our presence in the Neurology segment and making a difference to the lives of patients who have had the misfortune to suffer a stroke,’’ he added.
Each year about 15 Lakh people suffer from stroke in India. Cerebral Stroke is the third leading cause of deaths in India, as per the Global Burden of Disease Study 2013.